Crossmark

Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients

Crossref DOI link: https://doi.org/10.1016/j.reuma.2018.12.004

Published Print: 2021-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Torrente-Segarra, Vicenç

Fernández Prada, Manuel

Expósito, Rosa

Garrido Puñal, Noemí Patricia

Sánchez-Andrade, Amalia

Lamúa-Riazuelo, José Ramón

Olivé, Alejandro

Tovar, Juan Víctor
License Information

Text and Data Mining valid from 2021-01-01
More Information

This article is maintained by: Elsevier

Article Title: Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients

Journal Title: Reumatología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reuma.2018.12.004

Content Type: simple-article

Copyright: © 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.